Search Results - "Dunphy, Mark P.S"

The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology by Dunphy, Mark P. S., Pillarsetty, Nagavarakishore

“…Translational development of radiolabeled analogues or isotopologues of small molecule therapeutic drugs as clinical imaging biomarkers for optimizing patient…”
Get full text

Paradigms for Precision Medicine in Epichaperome Cancer Therapy by Pillarsetty, Nagavarakishore, Jhaveri, Komal, Taldone, Tony, Caldas-Lopes, Eloisi, Punzalan, Blesida, Joshi, Suhasini, Bolaender, Alexander, Uddin, Mohammad M., Rodina, Anna, Yan, Pengrong, Ku, Anson, Ku, Thomas, Shah, Smit K., Lyashchenko, Serge, Burnazi, Eva, Wang, Tai, Lecomte, Nicolas, Janjigian, Yelena, Younes, Anas, Batlevi, Connie W., Guzman, Monica L., Roboz, Gail J., Koziorowski, Jacek, Zanzonico, Pat, Alpaugh, Mary L., Corben, Adriana, Modi, Shanu, Norton, Larry, Larson, Steven M., Lewis, Jason S., Chiosis, Gabriela, Gerecitano, John F., Dunphy, Mark P.S.

“…Alterations in protein-protein interaction networks are at the core of malignant transformation but have yet to be translated into appropriate diagnostic…”
Get full text

Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET by Dunphy, Mark P.S, Lewis, Jason S

“…This review article discusses PET agents, other than (18)F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic…”
Get full text

High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology by Kadota, Kyuichi, Kachala, Stefan S, Nitadori, Jun-Ichi, Suzuki, Kei, Dunphy, Mark P S, Sima, Camelia S, Travis, William D, Rusch, Valerie W, Adusumilli, Prasad S

“…We have recently proposed to reclassify the pleomorphic subtype of epithelioid malignant pleural mesothelioma (MPM) as nonepithelioid (biphasic/sarcomatoid)…”
Get more information

The epichaperome is an integrated chaperome network that facilitates tumour survival by Rodina, Anna, Wang, Tai, Yan, Pengrong, Gomes, Erica DaGama, Dunphy, Mark P. S., Pillarsetty, Nagavarakishore, Koren, John, Gerecitano, John F., Taldone, Tony, Zong, Hongliang, Caldas-Lopes, Eloisi, Alpaugh, Mary, Corben, Adriana, Riolo, Matthew, Beattie, Brad, Pressl, Christina, Peter, Radu I., Xu, Chao, Trondl, Robert, Patel, Hardik J., Shimizu, Fumiko, Bolaender, Alexander, Yang, Chenghua, Panchal, Palak, Farooq, Mohammad F., Kishinevsky, Sarah, Modi, Shanu, Lin, Oscar, Chu, Feixia, Patil, Sujata, Erdjument-Bromage, Hediye, Zanzonico, Pat, Hudis, Clifford, Studer, Lorenz, Roboz, Gail J., Cesarman, Ethel, Cerchietti, Leandro, Levine, Ross, Melnick, Ari, Larson, Steven M., Lewis, Jason S., Guzman, Monica L., Chiosis, Gabriela

“…Chaperomes are dynamic assemblies of proteins that regulate cellular homeostasis but specific cellular stresses remodel chaperome components into a stable…”
Get full text

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC by Hellmann, Matthew D, Nabet, Barzin Y, Rizvi, Hira, Chaudhuri, Aadel A, Wells, Daniel K, Dunphy, Mark P S, Chabon, Jacob J, Liu, Chih Long, Hui, Angela B, Arbour, Kathryn C, Luo, Jia, Preeshagul, Isabel R, Moding, Everett J, Almanza, Diego, Bonilla, Rene F, Sauter, Jennifer L, Choi, Hyejin, Tenet, Megan, Abu-Akeel, Mohsen, Plodkowski, Andrew J, Perez Johnston, Rocio, Yoo, Christopher H, Ko, Ryan B, Stehr, Henning, Gojenola, Linda, Wakelee, Heather A, Padda, Sukhmani K, Neal, Joel W, Chaft, Jamie E, Kris, Mark G, Rudin, Charles M, Merghoub, Taha, Li, Bob T, Alizadeh, Ash A, Diehn, Maximilian

“…Treatment with PD-(L)1 blockade can produce remarkably durable responses in patients with non-small cell lung cancer (NSCLC). However, a significant fraction…”
Get full text

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions by Jhaveri, Komal, Ochiana, Stefan O, Dunphy, Mark Ps, Gerecitano, John F, Corben, Adriana D, Peter, Radu I, Janjigian, Yelena Y, Gomes-DaGama, Erica M, Koren, 3rd, John, Modi, Shanu, Chiosis, Gabriela

“…Heat shock protein 90 (HSP90) serves as a critical facilitator for oncogene addiction. There has been augmenting enthusiasm in pursuing HSP90 as an anticancer…”
Get more information

First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer by Dunphy, Mark P S, Pressl, Christina, Pillarsetty, Nagavarakishore, Grkovski, Milan, Modi, Shanu, Jhaveri, Komal, Norton, Larry, Beattie, Bradley J, Zanzonico, Pat B, Zatorska, Danuta, Taldone, Tony, Ochiana, Stefan O, Uddin, Mohammad M, Burnazi, Eva M, Lyashchenko, Serge K, Hudis, Clifford A, Bromberg, Jacqueline, Schöder, Heiko M, Fox, Josef J, Zhang, Hanwen, Chiosis, Gabriela, Lewis, Jason S, Larson, Steven M

“…I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under…”
Get full text

FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma by Kadota, Kyuichi, Colovos, Christos, Suzuki, Kei, Rizk, Nabil P., Dunphy, Mark P. S., Zabor, Emily C., Sima, Camelia S., Yoshizawa, Akihiko, Travis, William D., Rusch, Valerie W., Adusumilli, Prasad S.

“…Background We investigated the association between the newly proposed International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society…”
Get full text

Pharmacokinetic Assessment of 18 F-(2 S, 4 R )-4-Fluoroglutamine in Patients with Cancer by Grkovski, Milan, Goel, Reema, Krebs, Simone, Staton, Kevin D, Harding, James J, Mellinghoff, Ingo K, Humm, John L, Dunphy, Mark P S

“…F-(2S,4R)-4-fluoroglutamine ( F-FGln) is an investigational PET radiotracer for imaging tumor glutamine flux and metabolism. The aim of this study was to…”
Get full text

First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET by Krebs, Simone, Veach, Darren R, Carter, Lukas M, Grkovski, Milan, Fornier, Monica, Mauro, Michael J, Voss, Martin H, Danila, Daniel C, Burnazi, Eva, Null, Manda, Staton, Kevin, Pressl, Christina, Beattie, Bradley J, Zanzonico, Pat, Weber, Wolfgang A, Lyashchenko, Serge K, Lewis, Jason S, Larson, Steven M, Dunphy, Mark P S

“…We developed a first-of-kind dasatinib-derivative imaging agent, F-SKI-249380 ( F-SKI), and validated its use for noninvasive in vivo tyrosine kinase-targeted…”
Get full text

Pharmacokinetic Assessment of 18F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer by Grkovski, Milan, Goel, Reema, Krebs, Simone, Staton, Kevin D, Harding, James J, Mellinghoff, Ingo K, Humm, John L, Dunphy, Mark PS

“…18F-(2S,4R)-4-fluoroglutamine (18F-FGln) is an investigational PET radiotracer for imaging tumor glutamine flux and metabolism. The aim of this study was to…”
Get full text

Preoperative Consolidation-to-Tumor Ratio and SUVmax Stratify the Risk of Recurrence in Patients Undergoing Limited Resection for Lung Adenocarcinoma ≤2 cm by Nitadori, Jun-ichi, Bograd, Adam J., Morales, Eduardo A., Rizk, Nabil P., Dunphy, Mark P. S., Sima, Camelia S., Rusch, Valerie W., Adusumilli, Prasad S.

“…Purpose Limited resection is an increasingly utilized option for treatment of clinical stage IA lung adenocarcinoma (ADC) ≤2 cm (T1aN0M0), yet there are no…”
Get full text

In vivo microcartography and subcellular imaging of tumor angiogenesis: A novel platform for translational angiogenesis research by Dunphy, Mark P.S., Entenberg, David, Toledo-Crow, Ricardo, Larson, Steven M.

“…To eliminate the variable of tumor heterogeneity from a novel in vivo model of tumor angiogenesis. We developed a method to navigate tumor neovasculature in a…”
Get full text

Radionuclide techniques for identifying vulnerable plaque by Dunphy, Mark P S, Schoder, Heiko, Strauss, H William

“…There are 4 broad categories of radiolabeled agents: * Lipoproteins (8,9), methylated (10) and oxidized (11) lipoproteins, and antibodies recognizing oxidized…”
Get full text

Association of Vascular 18F-FDG Uptake with Vascular Calcification by Dunphy, Mark P.S, Freiman, Alvin, Larson, Steven M, Strauss, H. William

“…Both calcification and FDG uptake have been advocated as indicators of atheroma. Atheromas calcify as cells in the lesion undergo apoptosis and necrosis during…”
Get full text

Molecular imaging of atherosclerosis by Dunphy, Mark P. S., Strauss, H. William

“…Techniques are being developed for clinical molecular imaging of atherosclerosis to identify and characterize vulnerable plaques in each vascular territory…”
Get full text